PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen November 14, 2024
Researcher Discover Why Only Some People Experience Long-Term Benefits from Peanut Allergy Treatments October 29, 2024
